Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes.

ABSTRACT:

Aims/hypothesis

Immunotherapies such as Teplizumab can preserve residual beta cell function in individuals with newly diagnosed type 1 diabetes (T1D), but treatment response is variable. Currently, no biomarker exists to identify individuals most likely to benefit from immunotherapy. We believe that baseline serum metabolomic profiles can distinguish individuals who respond to treatment from nonresponders and predict therapeutic response.

Methods

Baseline serum samples from 41 individuals newly diagnosed with T1D enrolled in the AbATE trial (NCT00129259) were analyzed to identify metabolic predictors of response to Teplizumab therapy in the AbATE trial. Responders to Teplizumab, as per study protocol, were defined as individuals who exhibited less than a 40% decline in basel

SUBMITTER: Flammer ER 

PROVIDER: S-EPMC12755295 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature